Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spinal Modulation Inc.

Division of Abbott Laboratories Inc.
www.spinalmodulation.com

Latest From Spinal Modulation Inc.

St. Jude: Neuromodulators Could Be Key To Fighting Opioid Epidemic

As public-health officials continue to fight the opioid epidemic, a top executive at St. Jude Medical says neuromodulators can play a central role in providing better treatment options.

Medical Device Business Strategies

St. Jude's Newly Approved Axium Stimulator Could Be Market Game-Changer

St. Jude followed through on its 2015 acquisition of start-up Spinal Modulation with an FDA approval of the Axium neurostimulator for chronic intractable pain. It's the first such device to target the dorsal root ganglion and could expand the overall size of the spinal cord stimulation market.

Medical Device Clinical Trials

Neuro Medtech Investors Have Time (And Money) For The Pain

START-UP reviews five years of fundraising and exit activities for privately held medtech and diagnostics companies developing neurology treatments. Part 2 of our series on neuro-focused capital raising and bow-outs.

Medical Device

Device/Diagnostics Quarterly Deal Statistics, Q2 2015

At $1.8 billion, Q2 device financing nearly doubled the Q1 total, mainly from an increase in IPOs and early VC rounds, and acquisitions were slightly higher at $4.7 billion. Diagnostics funding also increased to $784 million from Q1's $597 million, and Danaher's monster $13.8 billion buy of life sciences company Pall headlined the second quarter's $15.6 billion total in diagnostics M&A activity.

Medical Device Deals
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Abbott Laboratories Inc.
  • Senior Management
  • David Wood, Pres. & CEO
    Jeff Kramer, PhD, CSO
    Dimas Jiménez, VP, Fin. & Admin.
    Dan Brounstein, VP, Market Dev.
  • Contact Info
  • Spinal Modulation Inc.
    Phone: (650) 543-6800
    1135 O'Brien Dr.
    Menlo Park, CA 94025
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register